Making way for suppressing the FGF19/FGFR4 axis in cancer

Nestor Prieto-Dominguez; Austin Y. Shull; Yong Teng

doi:10.4155/fmc-2018-0099

Making way for suppressing the FGF19/FGFR4 axis in cancer

Nestor Prieto-Dominguez, Austin Y. Shull, Yong Teng

Oral Biology & Dx Sciences

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

FGF19 is a noncanonical FGF ligand that can control a broad spectrum of physiological responses, which include bile acid homeostasis, liver metabolism and glucose uptake. Many of these responses are mediated by FGF19 binding to its FGFR4/β-klotho receptor complex and controlling activation of an array of intracellular signaling events. Overactivation of the FGF19/FGFR4 axis has been implicated in tumorigenic formation, progression and metastasis, and inhibitors of this axis have recently been developed for single agent use or in combination with other anticancer drugs. Considering the critical role of this receptor complex in cancer, this review focuses on recent developments and applications of FGF19/FGFR4-targeted therapeutics.

Original language	English (US)
Pages (from-to)	2457-2470
Number of pages	14
Journal	Future Medicinal Chemistry
Volume	10
Issue number	20
DOIs	https://doi.org/10.4155/fmc-2018-0099
State	Published - Oct 2018

Keywords

FGF19
FGFR4
anticancer
inhibitors
oncogenic role
signaling transduction
treatment regimens

ASJC Scopus subject areas

Molecular Medicine
Pharmacology
Drug Discovery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4155/fmc-2018-0099

Cite this

@article{a0241ce6ce684497a58143fece60b9ed,

title = "Making way for suppressing the FGF19/FGFR4 axis in cancer",

abstract = "FGF19 is a noncanonical FGF ligand that can control a broad spectrum of physiological responses, which include bile acid homeostasis, liver metabolism and glucose uptake. Many of these responses are mediated by FGF19 binding to its FGFR4/β-klotho receptor complex and controlling activation of an array of intracellular signaling events. Overactivation of the FGF19/FGFR4 axis has been implicated in tumorigenic formation, progression and metastasis, and inhibitors of this axis have recently been developed for single agent use or in combination with other anticancer drugs. Considering the critical role of this receptor complex in cancer, this review focuses on recent developments and applications of FGF19/FGFR4-targeted therapeutics.",

keywords = "FGF19, FGFR4, anticancer, inhibitors, oncogenic role, signaling transduction, treatment regimens",

author = "Nestor Prieto-Dominguez and Shull, {Austin Y.} and Yong Teng",

note = "Funding Information: This work was supported in part by start-up funding of Augusta University. N Prieto-Dominguez is conducting his study under supervision of Teng at Augusta University supported by the Spanish Ministry of Education, Culture and Sports ({\textquoteleft}Becas FPU 2013{\textquoteright}, reference FPU13/04173 EST 16/00783). The authors declare no competing financial interests. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2018 2018 Newlands Press.",

year = "2018",

month = oct,

doi = "10.4155/fmc-2018-0099",

language = "English (US)",

volume = "10",

pages = "2457--2470",

journal = "Future Medicinal Chemistry",

issn = "1756-8919",

publisher = "Future Science",

number = "20",

}

TY - JOUR

T1 - Making way for suppressing the FGF19/FGFR4 axis in cancer

AU - Prieto-Dominguez, Nestor

AU - Shull, Austin Y.

AU - Teng, Yong

N1 - Funding Information: This work was supported in part by start-up funding of Augusta University. N Prieto-Dominguez is conducting his study under supervision of Teng at Augusta University supported by the Spanish Ministry of Education, Culture and Sports (‘Becas FPU 2013’, reference FPU13/04173 EST 16/00783). The authors declare no competing financial interests. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: © 2018 2018 Newlands Press.

PY - 2018/10

Y1 - 2018/10

N2 - FGF19 is a noncanonical FGF ligand that can control a broad spectrum of physiological responses, which include bile acid homeostasis, liver metabolism and glucose uptake. Many of these responses are mediated by FGF19 binding to its FGFR4/β-klotho receptor complex and controlling activation of an array of intracellular signaling events. Overactivation of the FGF19/FGFR4 axis has been implicated in tumorigenic formation, progression and metastasis, and inhibitors of this axis have recently been developed for single agent use or in combination with other anticancer drugs. Considering the critical role of this receptor complex in cancer, this review focuses on recent developments and applications of FGF19/FGFR4-targeted therapeutics.

AB - FGF19 is a noncanonical FGF ligand that can control a broad spectrum of physiological responses, which include bile acid homeostasis, liver metabolism and glucose uptake. Many of these responses are mediated by FGF19 binding to its FGFR4/β-klotho receptor complex and controlling activation of an array of intracellular signaling events. Overactivation of the FGF19/FGFR4 axis has been implicated in tumorigenic formation, progression and metastasis, and inhibitors of this axis have recently been developed for single agent use or in combination with other anticancer drugs. Considering the critical role of this receptor complex in cancer, this review focuses on recent developments and applications of FGF19/FGFR4-targeted therapeutics.

KW - FGF19

KW - FGFR4

KW - anticancer

KW - inhibitors

KW - oncogenic role

KW - signaling transduction

KW - treatment regimens

UR - http://www.scopus.com/inward/record.url?scp=85055602473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055602473&partnerID=8YFLogxK

U2 - 10.4155/fmc-2018-0099

DO - 10.4155/fmc-2018-0099

M3 - Review article

C2 - 30325210

AN - SCOPUS:85055602473

SN - 1756-8919

VL - 10

SP - 2457

EP - 2470

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

IS - 20

ER -

Making way for suppressing the FGF19/FGFR4 axis in cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this